Study S002542

Impact of Incretin-mimetic Hypoglycaemic Drugs on Diabetic Retinopathy in Type 2 Diabetic Patients and Study of Biomarkers in the Development of Severe Retinopathy: Angiosafe-T2D Study 2

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02671864
Acronym: ANGIOSAFE2
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Masking: NONE
Status: UNKNOWN
Enrollment: 7200
Start: 2016-04-11
Primary completion: 2022-04-11
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Conditions: Type 2 Diabetes
Interventions: OTHER:1: incretin-based therapy; OTHER:2: other antidiabetic
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Prevalence of Severe DR at V1 (inclusion) [at inclusion]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006583	Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study. Gaborit B, The Journal of clinical endocrinology and metabolism	2020	Randomized trial	PMID 31589290 DOI	cites ClinicalTrials.gov:NCT02671864; registry reference DERIVED:31589290